

Titre de la publication	Journal, N°	Année	Auteurs	equipe	Publi en collab
Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic 18F Fluorodeoxyglucose PET.	Radiology. 2016 Nov 15:160329.	2016	Meijer TW, de Geus-Oei LF, Visser EP, Oyen WJ, Looijen-Salamon MG, Visvikis D , Verhagen AF, Bussink J, Vriens D.	B1	
Radiomics in PET/CT: more than meets the eye?	J Nucl Med. 2016 Nov 3.	2016	Hatt M, Tixier F, Visvikis D, Cheze Le Rest C.	B1, P4	1
18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer.	Eur J Nucl Med Mol Imaging. 2016 Dec;43(13):2324-2335	2016	Lasnon C, Majdoub M, Lavigne B, Do P, Madelaine J, Visvikis D, Hatt M , Aide N.	B1	
The Impact of Optimal Respiratory Gating and Image Noise on Evaluation of Intratumor Heterogeneity on 18F-FDG PET Imaging of Lung Cancer.	J Nucl Med. 2016 Nov;57(11):1692-1698.	2016	Grootjans W, Tixier F , van der Vos CS, Vriens D, Le Rest CC , Bussink J, Oyen WJ, de Geus-Oei LF, Visvikis D , Visser EP.	B1, P4	1
Reliability of PET/CT shape and heterogeneity features in functional and morphological components of Non-Small Cell Lung Cancer tumors: a repeatability analysis in a prospective multi-center cohort.	J Nucl Med. 2016 Oct 20.	2016	Desseroit MC, Tixier F , Weber WA, Siegel BA, Cheze Le Rest C, Visvikis D, Hatt M.	B1, P4	1
4D MR and attenuation map generation in PET/MR imaging using 4D PET derived deformation matrices: a feasibility study for lung cancer applications.	J Nucl Med. 2016 Oct 13.	2016	Fayad H , Schmidt H, Kuestner T, Visvikis D.	B1	
Patient positioning in radiotherapy based on surface imaging using time of flight cameras.	Med Phys. 2016 Aug;43(8):4833.	2016	Gilles M, Fayad H, Migliorini P, Clement JF , Scheib S, Cozzi L, Bert J, Bousson N, Schick U, Pradier O, Visvikis D.	B1, B3	1
Erratum to: Development of a nomogram combining clinical staging with 18F-FDG PET/CT image features in non-small-cell lung cancer stage I-III.	Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1933.	2016	Desseroit MC, Visvikis D, Tixier F , Majdoub M, Perdrisot R, Guillevin R, Le Rest CC, Hatt M.	B1, P4	1
Performance of automatic image segmentation algorithms for calculating total lesion glycolysis for early response monitoring in non-small cell lung cancer patients during concomitant chemoradiotherapy.	Radiother Oncol. 2016 Jun;119(3):473-9	2016	Grootjans W, Usmanij EA, Oyen WJ, van der Heijden EH, Visser EP, Visvikis D, Hatt M , Bussink J, de Geus-Oei LF.	B1	
Accelerated GPU based SPECT Monte Carlo simulations.	Phys Med Biol. 2016 Jun 7;61(11):4001-18.	2016	Garcia MP, Bert J , Benoit D, Bardiès M, Visvikis D.	B1	
(18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status.	Br J Radiol. 2016 Jul;89(1063):2016	2016	Lovinfosse P, Koopmansch B, Lambert F, Jodogne S, Kustermans G, Hatt M, Visvikis D , Seidel L, Polus M, Albert A, Delvenne P, Hustinx R.	B1	
New hybrid voxelized/analytical primitive in Monte Carlo simulations for medical applications.	Phys Med Biol. 2016 May 7;61(9):3347-64.	2016	Bert J, Lemaréchal Y, Visvikis D.	B1	
Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric 18F-FDG PET Images in Non-Small Cell Lung Cancer.	J Nucl Med. 2016 Jul;57(7):1033-9.	2016	Tixier F , Vriens D, Cheze-Le Rest C, Hatt M , Disselhorst JA, Oyen WJ, de Geus-Oei LF, Visser EP, Visvikis D.	B1	
Innovations in Small-Animal PET/MR Imaging Instrumentation.	PET Clin. 2016 Apr;11(2):105-18.	2016	Tsoumpas C, Visvikis D , Loudos G.	B1	
Development of a nomogram combining clinical staging with (18)F-FDG PET/CT image features in non-small-cell lung cancer stage I-III.	Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1477-85.	2016	Desseroit MC, Visvikis D, Tixier F , Majdoub M, Perdrisot R, Guillevin R, Cheze Le Rest C, Hatt M.	B1, P4	1
FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.	Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1453-60.	2016	Lovinfosse P, January ZL, Coucke P, Jodogne S, Bernard C, Hatt M, Visvikis D , Jansen N, Duysinx B, Hustinx R.	B1	
[Prognostic value of the metabolically active tumour volume.]	Cancer Radiother. 2016 Feb;20(1):24-9.	2016	Paumier A, Marquis A, Trémolières P, Lacombe M, Capitain O, Septans AL, Peyraga G, Gustin P, Vénara A, Ménager É, Visvikis D, Couturier O , Rio E, Hatt M.	B1, A3	1

Motion correction using anatomical information in PET/CT and PET/MR hybrid imaging.	Q J Nucl Med Mol Imaging. 2016 Mar;60(1):12-24.	2016	Fayad H, Lamare F, Merlin T, Visvikis D.	B1	
An atypical sarcoidosis involvement in FDG PET/CT: A case report.	Medicine (Baltimore). 2016 Dec;95(52)	2016	Robin P, Benigni P, Feger B, Salaun PY, Abgral R.	B2	
Correlation between FDG hotspots on pre-treatment PET/CT and preferential sites of local relapse after chemo-radiotherapy for head and neck squamous cell carcinoma.	Head Neck. 2016 Dec 29.	2016	Chaput A, Calais J, Robin R, Thureau S, Bourhis D , Modzelewski R, Schick U, Vera P, Salaün PY, Abgral R.	B2, B3	1
Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus Rituximab: comparison between Deauville 5-point scale and International Harmonization Project criteria.	Q J Nucl Med Mol Imaging. 2016 Nov 30	2016	Lombion N, Robin P, Tempescul A, LE Roux PY, Schick U , Guillerm G, Ianotto JC, Berthou C, Salaün PY, Abgral R.	B2, B3	1
Does PET SUV Harmonization Affect PERCIST Response Classification?	J Nucl Med. 2016 Nov;57(11):1699-1706.	2016	Quak E, Le Roux PY , Lasnon C, Robin P, Hofman MS, Bourhis D, Callahan J, Binns DS, Desmots C, Salaun PY , Hicks RJ, Aide N.	B2	
Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial.	Lancet Oncol. 2016 Feb;17(2):193-9.	2016	Robin P, Le Roux PY , Planquette B, Accassat S, Roy PM, Couturaud F, Ghazzar N, Prevot-Bitot N, Couturier O , Delluc A, Sanchez O, Tardy B, Le Gal G, Salaun PY ; MVTEP study group..	B2, A2	1
Prognostic evaluation of percentage variation of metabolic tumor burden calculated by dual-phase (18) FDG PET-CT imaging in patients with head and neck cancer.	Head Neck. 2016 Apr;38 Suppl 1:E600-6.	2016	Abgral R , Valette G, Robin P, Rousset J, Keromnes N, Le Roux PY , Marianowski R, Salaün PY.	B2	
FDG PET/CT for Initial Staging of Diffuse Large B-Cell Lymphoma: Is Diffuse Bone Marrow Uptake a Reflection of Disease Involvement?	J Bone Marrow Res 2016;4:164.	2016	Keromnes N, Le Roux PY , Tempescul A, Abgral R , Robin P, Lombion N, Querellou S, Palard X, Berthou C, Salaün PY.	B2	
Gallium-68 perfusion positron emission tomography/computed tomography to assess pulmonary function in lung cancer patients undergoing surgery	Cancer Imaging. 2016 Aug 20;16(1):24.	2016	Le Roux PY , Leong TL, Barnett SA, Hicks RJ, Callahan J, Eu P, Manser R, Hofman MS	B2	
[Establishing margins from CTV to PTV in breast cancer treatment.]	Cancer Radiother. 2016 Oct;20(6-7):640-4.	2016	Cabanne A, Schick U, Pradier O , Rivera S.	B3	
Benefits of breathing-adapted radiation therapy for breast cancer.	Cancer Radiother. 2016 Feb;20(1):30-5.	2016	Vourch S, Miglierini P , Miranda O, Malhaire JP, Boussion N, Pradier O, Schick U.	B3	
CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.	Mol Cancer Ther. 2016 Sep;15(9):2042-54.	2016	Barker HE, Patel R, McLaughlin M, Schick U , Zaidi S, Nutting CM, Newbold KL, Bhide S, Harrington KJ.	B3	
FDG PET-CT for solitary pulmonary nodule and lung cancer: Literature review.	Diagn Interv Imaging. 2016 Oct;97(10):1003-1017.	2016	Groheux D, Quere G, Blanc E, Lemarignier C, Vercellino L, de Margerie-Mellon C, Merlet P, Querellou S.	B2	
Definition of the Labile Capping Bond Effect in Lanthanide Complexes.	Chemistry. 2016 Nov 8.	2016	Rodríguez-Rodríguez A, Regueiro-Figueroa M, Esteban-Gómez D, Rodríguez-Blas T, Patinec V, Tripier R , Tircsó G, Carniato F, Botta M, Platas-Iglesias C.	B4	
The Relationship between NMR Chemical Shifts of Thermally Polarized and Hyperpolarized 89 Y Complexes and Their Solution Structures.	Chemistry. 2016 Nov 7;22(46):16657-16667.	2016	Xing Y, Jindal AK, Regueiro-Figueroa M, Le Fur M , Kervarec N, Zhao P, Kovacs Z, Valencia L, Pérez-Lourido P, Tripier R , Esteban-Gómez D, Platas-Iglesias C, Sherry AD.	B4	
Cyclams with Ambidentate Methylthiazolyl Pendants for Stable, Inert, and Selective Cu(II) Coordination.	Inorg Chem. 2016 Jan 19;55(2):619-32.	2016	Rodríguez-Rodríguez A, Halime Z , Lima LM, Beyler M, Deniaud D , Le Poul N, Delgado R, Platas-Iglesias C, Patinec V, Tripier R.	B4, N7	1
Correction: New synthesis of phenyl-isothiocyanate C-functionalised cyclams. Bioconjugation and (64)Cu phenotypic PET imaging studies of multiple myeloma with the te2a derivative.	Org Biomol Chem. 2016 Apr 12;14(15):3838.	2016	Halime Z, Frindel M , Camus N, Orain PY, Lacombe M , Bernardeau K, Chérel M, Gestin JF, Faivre-Chauvet A, Tripier R.	B4, N1	1

Improving the stability and inertness of Cu(II) and Cu(I) complexes with methylthiazolyl ligands by tuning the macrocyclic structure.	Dalton Trans. 2016 May 7;45(17):7406-20.	2016	Le Fur M, Beyler M , Le Poul N, Lima LM, Le Mest Y, Delgado R, Platas-Iglesias C, Patinec V, Tripier R.	B4	
Cationic Two-Photon Lanthanide Bioprobes Able to Accumulate in Live Cells.	Inorg Chem. 2016 Jul 18;55(14):7020-5.	2016	Bui AT, Beyler M, Liao YY, Grichine A, Duperray A, Mulatier JC, Guennic BL, Andraud C, Maury O, Tripier R.	B4	
Pyclen Tri-n-butylphosphonate Ester as Potential Chelator for Targeted Radiotherapy: From Yttrium(III) Complexation to (90)Y Radiolabeling.	Inorg Chem. 2016 Aug 15;55(16):8003-12.	2016	Le Fur M, Beyler M, Lepareur N , Fougère O, Platas-Iglesias C, Rousseaux O, Tripier R.	B4, R1	1
Characterization of the distribution, retention, and efficacy of internal radiation of 188Re-lipid nanocapsules in an immunocompromised human glioblastoma model.	J Neurooncol. 2016 Oct 25.	2016	Cikankowitz A, Clavreul A, Tétaud C, Lemaire L, Rousseau A, Lepareur N, Dabli D, Bouchet F, Garcion E, Menei P, Couturier O, Hindré F.	A1, A3, A4, R1	1
68Ga and 188Re Starch-Based Microparticles as Theranostic Tool for the Hepatocellular Carcinoma: Radiolabeling and Preliminary In Vivo Rat Studies.	PLoS One. 2016 Oct 14;11(10):e0164626	2016	Verger E, Drion P, Meffre G, Bernard C, Duwez L, Lepareur N, Couturier O, Hindré F , Hustinx R, Lacoeuille F.	A1, A3	1
Dendrimers as Innovative Radiopharmaceuticals in Cancer Radionanotherapy.	Biomacromolecules. 2016 Oct 10;17(10):3103-3114.	2016	Liko F, Hindré F , Fernandez-Megia E.	A1	
Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells.	BMC Cancer. 2016 Feb 1;16:51.	2016	Legendre C, Avril S, Guillet C, Garcion E.	A1	
Nucleic-Acid Delivery Using Lipid Nanocapsules.	Curr Pharm Biotechnol. 2016;17(8):723-7. Review.	2016	Lagarce F, Passirani C.	A1	
An MRI-based classification scheme to predict passive access of 5 to 50-nm large nanoparticles to tumors.	Sci Rep. 2016 Feb 19;6:21417.	2016	Karageorgis A, Dufort S, Sancey L, Henry M, Hirsjärvi S, Passirani C, Benoit JP , Gravier J, Texier I, Montigon O, Benmerad M, Siroux V, Barbier EL, Coll JL.	A1	
How to design the surface of peptide-loaded nanoparticles for efficient oral bioavailability?	Adv Drug Deliv Rev. 2016 Nov 15;106(Pt B):320-336.	2016	Malhaire H, Gimel JC, Roger E, Benoît JP , Lagarce F.	A1	
[Can positron emission tomography assessment of response to treatment help to individualize use of erlotinib in non-small cell lung cancer?]	Rev Mal Respir. 2016 Nov;33(9):817-823.	2016	Hureaux J, Couturier O, Lacœuille F, Bouchet F , Chouaïd C, Saulnier P, Urban T; les investigateurs du projet..	A5, A1, A3	1
Corneal graft rejection in a patient treated with nivolumab for primary lung cancer.	Lung Cancer. 2016 Dec;102:28-29.	2016	Le Fournis S, Gohier P, Urban T, Jeanfaivre T, Hureaux J.	A5	
146P: The potential role for consolidative radiotherapy in oligometastatic non small cell lung cancer through the prism of pattern of failure analysis.	J Thorac Oncol. 2016 Apr;11(4 Suppl):S121.	2016	Gustin P, Tremolieres P, Peyraga G, Hureaux J , Mege M, Paumier A.	A5	
Endobronchial Metastases from Melanoma: A Survival Analysis.	Clin Respir J. 2016 Jan 20.	2016	Chaussende A, Hermant C, Tazi-Mezalek R, Favrolt N, Hureaux J , Fournier C, Lorut C, Paganin F, Ngo MT, Vandemoortele T, Anevlavis S, Froudarakis ME, Vergnon JM; GELF (Group d'Endoscopie Langue Française)..	A5	
Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.	J Nucl Med. 2016 Oct;57(10):1505-1511.	2016	Bodet-Milin C, Faivre-Chauvet A, Carlier T, Rauscher A, Bourgeois M, Cerato E , Rohmer V, Couturier O , Drui D, Goldenberg DM, Sharkey RM, Barbet J, Kraeber-Bodere F.	A5, N1, N8	1
For avid glucose tumors, the SUV peak is the most reliable parameter for [(18)F]FDG-PET/CT quantification, regardless of acquisition time.	EJNMMI Res. 2016 Dec;6(1):21.	2016	Sher A, Lacoeuille F , Fosse P, Vervueren L, Cahouet-Vannier A, Dabli D, Bouchet F, Couturier O.	A3	
High-Dose Hypofractionated Radiation Therapy for Noncompressive Vertebral Metastases in Combination With Zoledronate: A Phase 1 Study.	Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):840-847.	2016	Pichon B, Campion L, Delpon G , Thillays F, Carrie C, Cellier P , Pommier P, Laude C, Mervoyer A, Hamidou H, Mahé MA, Supiot S.	A6, N10	1
[Role of radiotherapy in the management of node-positive prostate cancer].	Cancer Radiother. 2016 Oct;20(6-7):442-4.	2016	Supiot S , Doré M, Rio E, Cellier P , Mesguez-Nebout N, Goineau A.	A6, N10	1

Alteration of cathepsin D trafficking induced by hypoxia and extracellular acidification in MCF-7 breast cancer cells.	Biochimie. 2016 Feb;121:123-30.	2016	Achour O, Ashraf Y, Bridiau N, Kacem M, Poupard N , Bordenave-Juchereau S, Sannier F, Lamerant-Fayel N, Kieda C, Liaudet-Coopman E, Piot JM, Maugard T, Fruitier-Arnaudin I .	LR1	
Anti-heparanase activity of ultra-low-molecular-weight heparin produced by physicochemical depolymerization.	Carbohydr Polym. 2016 Jan 1;135:316-23.	2016	Achour O, Poupard N , Bridiau N, Bordenave Juchereau S, Sannier F, Piot JM, Fruitier Arnaudin I , Maugard T.	LR1	
Immuno-PET for Clinical Theranostic Approaches.	Int J Mol Sci. 2016 Dec 28;18(1).	2016	Bailly C , Cléry PF, Faivre-Chauvet A , Bourgeois M , Guérard F , Haddad F , Barbet J , Chérel M , Kraeber-Bodéré F , Carlier T , Bodet-Milin C .	N1, N5, N8	1
Deuteron induced Tb-155 production, a theranostic isotope for SPECT imaging and auger therapy.	Appl Radiat Isot. 2016 Dec;118:281-289.	2016	Duchemin C, Guertin A, Haddad F , Michel N, Métivier V.	N4, N5	1
How to produce high specific activity tin-117m using alpha particle beam.	Appl Radiat Isot. 2016 Sep;115:113-24.	2016	Duchemin C, Essayan M, Guertin A, Haddad F , Michel N, Métivier V.	N4, N5	1
ImmunoPET to help stratify patients for targeted therapies and to improve drug development.	Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2166-2168.	2016	Kraeber-Bodere F , Bailly C , Chérel M , Chatal JF .	N1, N5, N8	1
Radioimmunotherapy: From Current Clinical Success to Future Industrial Breakthrough?	J Nucl Med. 2016 Mar;57(3):329-31.	2016	Kraeber-Bodéré F , Barbet J , Chatal JF .	N1, N5	1
Advances on the Determination of the Astatine Pourbaix Diagram: Predomination of AtO(OH)2 (-) over At(-) in Basic Conditions.	Chemistry. 2016 Feb 24;22(9):2964-71.	2016	Sergentu DC, Teze D, Sabatié-Gogova A, Alliot C , Guo N, Bassal F, Silva ID, Deniaud D , Maurice R, Champion J , Galland N , Montavon G .	N4, N5, N7	1
Recent advances in cancer treatment by iron chelators.	Bioorg Med Chem Lett. 2016 Jan 15;26(2):251-6.	2016	Corcé V, Gouin SG, Renaud S, Gaboriau F , Deniaud D .	N7, R6	1
Radioimmunotherapy in non-Hodgkin lymphoma: Prediction and assessment of response.	Crit Rev Oncol Hematol. 2016 Nov;107:182-189. Review.	2016	Eskian M, Khorasanizadeh M, Kraeber-Bodere F , Rezaei N.	N8, N9	1
Revisiting the Robustness of PET-Based Textural Features in the Context of Multi-Centric Trials.	PLoS One. 2016 Jul 28;11(7):e0159984	2016	Bailly C , Bodet-Milin C , Couespel S, Necib H , Kraeber-Bodéré F , Ansquer C , Carlier T .	N1, N8	1
Quantitative Evaluation of Therapeutic Response by FDG-PET-CT in Metastatic Breast Cancer.	Front Med (Lausanne). 2016 May 9;3:19.	2016	Goulon D, Necib H, Henaff B, Rousseau C , Carlier T , Kraeber-Bodere F .	N1, N8, N9	1
Laparoscopic sentinel lymph node dissection in prostate cancer patients: the additional value depends on preoperative data.	Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1849-56.	2016	Rousseau C , Rousseau T, Mathieu C, Lacoste J, Potiron E, Aillet G, Nevoux P, Le Coguic G, Campion L, Kraeber-Bodéré F .	N1, N9	1
[Alpha-Radioimmunotherapy: principle and relevance in anti-tumor immunity].	Med Sci (Paris). 2016 Apr;32(4):362-9.	2016	Ménager J , Gorin JB , Fichou N , Gouard S , Morgenstern A, Bruchertseifer F, Davodeau F , Kraeber-Bodéré F , Chérel M , Gaschet J , Guilloux Y .	N1, N9	1
Radioimmunotherapy for Treatment of Acute Leukemia.	Semin Nucl Med. 2016 Mar;46(2):135-46.	2016	Bodet-Milin C , Kraeber-Bodéré F , Eugène T , Guérard F , Gaschet J , Bailly C , Mougin M , Bourgeois M , Faivre-Chauvet A , Chérel M , Chevallier P.	N1, N8, N9	1
The archaeal "7 kDa DNA-binding" proteins: extended characterization of an old gifted family.	Sci Rep. 2016 Nov 17;6:37274.	2016	Kalichuk V , Béhar G , Renodon-Cornière A , Danovski G, Obal G, Barbet J , Mouratou B , Pecorari F .	N1	
(211)At-labeled agents for alpha-immunotherapy: On the in vivo stability of astatine-agent bonds.	Eur J Med Chem. 2016 Jun 30;116:156-64.	2016	Ayed T, Pilmé J, Tézé D, Bassal F, Barbet J , Chérel M , Champion J, Maurice R, Montavon G , Galland N.	N1, N4, N5	1
Production and characterization of monoclonal antibodies specific for canine CD138 (syndecan-1) for nuclear medicine preclinical trials on spontaneous tumours.	Vet Comp Oncol. 2016 Apr 14.	2016	Diab M , Nguyen F , Berthaud M, Maurel C , Gaschet J , Verger E , Ibisch C , Rousseau C , Chérel M , Abadie J , Davodeau F .	N1, N6, N9	1

Long-Term Toxicity of 213Bi-Labelled BSA in Mice.	PLoS One. 2016 Mar 16;11(3):e0151330.	2016	Dorso L , Bigot-Corbel E, Abadie J , Diab M , Gouard S , Bruchertseifer F, Morgenstern A, Maurel C , Chérel M , Davodeau F .	N1, N6	1
Ionic liquid supported organotin reagents to prepare molecular imaging and therapy agents.	Org Biomol Chem. 2016 Feb 14;14(6):2121-6.	2016	Rajerison H, Faye D, Roumesy A, Louaisil N, Boeda F, Faivre-Chauvet A , Gestin JF , Legoupy S.	N1	
Unexpected Behavior of the Heaviest Halogen Astatine in the Nucleophilic Substitution of Aryliodonium Salts.	Chemistry. 2016 Aug 22;22(35):12332-9.	2016	Guérard F , Lee YS, Baidoo K, Gestin JF , Brechbiel MW.	N1	
A gate evaluation of the sources of error in quantitative 90Y PET.	Med Phys. 2016 Oct;43(10):5320.	2016	Strydhorst J, Carlier T , Dieudonné A, Conti M, Buvat I.		
Affitins for protein purification by affinity magnetic fishing.	J Chromatogr A. 2016 Jul 29;1457:50-8.	2016	Fernandes CS, Dos Santos R, Ottengy S, Viacinski AC, Béhar G , Mouratou B , Pecorari F , Roque AC.	N1	
Affitins as robust tailored reagents for affinity chromatography purification of antibodies and non-immunoglobulin proteins.	J Chromatogr A. 2016 Apr 8;1441:44-51.	2016	Béhar G, Renodon-Cornière A, Mouratou B, Pecorari F .	N1	
Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside.	Oncotarget. 2016 Jul 5;7(27):41172-41185.	2016	Fleurence J, Coehonneau D , Fougeray S , Oliver L, Geraldo F, Terme M , Dorvillius M, Loussouarn D, Vallette F, Paris F , Birklé S .	N1	
Oxidative stress disassembles the p38/NPM/PP2A complex, which leads to modulation of nucleophosmin-mediated signaling to DNA damage response.	FASEB J. 2016 Aug;30(8):2899-914.	2016	Guillonneau M, Paris F , Dutoit S, Estephan H, Bénéteau E, Huot J, Corre I .	N2	
Plasma ceramide, a real-time predictive marker of pulmonary and hepatic metastases response to stereotactic body radiation therapy combined with irinotecan.	Radiother Oncol. 2016 May;119(2):229-35.	2016	Dubois N, Rio E, Ripoche N, Ferchaud-Roucher V, Gaugler MH, Campion L, Krempf M, Carrie C, Mahé M , Mirabel X, Paris F .	N2	
Validation of fast Monte Carlo dose calculation in small animal radiotherapy with EBT3 radiochromic films.	Phys Med Biol. 2016 May 7;61(9):3521-35.	2016	Noblet C , Chiavassa S , Smekens F, Sarrut D, Passal V, Suhard J, Lisbona A , Paris F , Delpont G .	N10	
Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma.	Blood. 2016 Dec 15;128(24):2808-2818.	2016	Chiron D, Bellanger C, Papin A, Tessoulin B, Dousset C, Maiga S, Moreau A, Esbelin J, Trichet V, Chen-Kiang S, Moreau P, Touzeau C, Le Gouill S, Amiot M, Pellat-Deceunynck C.	N3	
TGF-β Signaling in Bone Remodeling and Osteosarcoma Progression.	J Clin Med. 2016 Nov 3;5(11). pii: E96. Review.	2016	Lamora A, Talbot J, Mullard M, Brounais-Le Royer B, Redini F , Verrecchia F.	N3	
Proteoglycans as Target for an Innovative Therapeutic Approach in Chondrosarcoma: Preclinical Proof of Concept.	Mol Cancer Ther. 2016 Nov;15(11):2575-2585.	2016	Peyrode C, Weber V, Voissière A, Maisonia-Besset A, Vidal A, Auzeloux P, Gaumet V, Borel M, Dauplat MM, Quintana M, Degoul F, Rédini F , Chezal JM, Miot-Noirault E.	N3	
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.	Lancet Oncol. 2016 Aug;17(8):1070-80.	2016	Piperno-Neumann S, Le Deley MC, Rédini F , Pacquement H, Marec-Bérard P, Petit P, Brisse H, Lervat C, Gentet JC, Entz-Werlé N, Italiano A, Corradini N, Bompas E, Penel N, Tabone MD, Gomez-Brouchet A, Guinebretière JM, Mascard E, Gouin F, Chevance A, Bonnet N, Blay JY, Brugières L; Sarcoma Group of UNICANCER.; French Society of Pediatric Oncology (SFCE).; French Sarcoma Group (GSF-GETO)..	N3	
Opposite Effects of Soluble Factors Secreted by Adipose Tissue on Proliferating and Quiescent Osteosarcoma Cells.	Plast Reconstr Surg. 2016 Mar;137(3):865-75.	2016	Avril P, Duteille F, Ridet P, Heymann MF, De Pinieux G, Rédini F , Blanchard F, Heymann D, Trichet V, Perrot P.	N3	

The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease.	Oncotarget. 2016 Feb 23;7(8):8613-24	2016	Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Grünewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, Lawlor E, Lessnick S, Ludwig J, Meltzer P, Metzler M, Mora J, Moriggl R, Nakamura T, Papamarkou T, Radic Sarikas B, Rédini F , Richter GH, Rossig C, Schadler K, Schäfer BW, Scotlandi K, Sheffield NC, Shelat A, Snaar-Jagalska E, Sorensen P, Stegmaier K, Stewart E, Sweet-Cordero A, Szu Hai K, Tirado OM, Tirode F, Toretsky J, Tsafou K, Üren A, Zinovyev A, Delattre O.	N3		
RANK-RANKL signalling in cancer.	Biosci Rep. 2016 Aug 5;36(4)	2016	Renema N, Navet B, Heymann MF, Lezot F , Heymann D.	N3		
ANp63α Silences a miRNA Program to Aberrantly Initiate a Wound-Healing Program That Promotes TGFβ-Induced Metastasis.	Cancer Res. 2016 Jun 1;76(11):3236-51.	2016	Rodriguez Calleja L, Jacques C, Lamoureux F, Baud'huin M, Tellez Gabriel M, Quillard T, Sahay D, Perrot P, Amiaud J, Charrier C, Brion R, Lecanda F, Verrecchia F , Heymann D, Ellisen LW, Ory B.	N3		
Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression.	Clin Cancer Res. 2016 May 15;22(10):2520-33.	2016	Ory B, Baud'huin M, Verrecchia F , Royer BB, Quillard T, Amiaud J, Battaglia S, Heymann D, Redini F, Lamoureux F.	N3		
Non-ocular melanomas in cats: a retrospective study of 30 cases.	J Feline Med Surg. 2016 Jan 14.	2016	Chamel G, Abadie J , Albaric O, Labrut S, Ponce F, Ibisch C .	N6		
Cure of human ovarian carcinoma solid xenografts by fractionated [211At] alpha-radioimmunotherapy: Influence of tumor absorbed dose and effect on long-term survival.	J Nucl Med. 2016 Sep 29. pii: jnumed.116.178327	2016	Bäck TA, Chouin N , Lindegren S, Kahu H, Jensen H, Albertsson P, Palm S.	N6		
Unraveling the hydration-induced ground-state change of AtO+ by relativistic and multiconfigurational wave-function-based methods.	Phys Chem Chem Phys. 2016 Dec 7;18(48):32703-32712.	2016	Sergentu DC, Réal F, Montavon G , Galland N, Maurice R.	N4		
The Heaviest Possible Ternary Trihalogen Species, IAtBr-, Evidenced in Aqueous Solution: An Experimental Performance Driven by Computations.	Angew Chem Int Ed Engl. 2016 Dec 5;55(49):15369-15372.	2016	Guo N, Sergentu DC, Teze D, Champion J, Montavon G , Galland N, Maurice R.	N4		
Scrutinizing "Invisible" astatine: A challenge for modern density functionals.	J Comput Chem. 2016 Jun 5;37(15):1345-54.	2016	Sergentu DC, David G, Montavon G , Maurice R, Galland N.	N4		
Scandium(III) complexes of monophosphorus acid DOTA analogues: a thermodynamic and radiolabelling study with (44)Sc from cyclotron and from a (44)Ti/(44)Sc generator.	Dalton Trans. 2016 Jan 28;45(4):1398-409.	2016	Kerdjoudj R, Pniok M, Alliot C, Kubíček V, Havlíčková J, Rösch F, Hermann P, Huclier-Markai S .	N4		
[Prostate cancer brachytherapy].	Cancer Radiother. 2016 Sep;20 Suppl:S210-5.	2016	Pommier P, Guérif S , Peiffert D, Créhange G, Hannoun-Lévi JM, de Crevoisier R .	P2, R2		1
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.	Lancet Oncol. 2016 Jun;17(6):747-56.	2016	Carrie C, Hasbini A, de Laroche G, Richaud P, Guerif S , Latorzeff I, Supiot S , Bosset M, Lagrange JL, Beckendorf V, Lesaunier F, Dubray B, Wagner JP, N'Guyen TD, Suchaud JP, Créhange G, Barbier N, Habibian M, Ferlay C, Fournere P, Ruffion A, Dussart S.	P2, N10		1
DNA-PKcs Expression Is a Predictor of Biochemical Recurrence After Permanent Iodine 125 Interstitial Brachytherapy for Prostate Cancer.	Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):965-72.	2016	Molina S, Guerif S , Garcia A, Debais C, Irani J, Fromont G.	P2		
Profit (Prostate Fractionated Irradiation Trial) : résultats d'une étude internationale randomisée comparant deux schémas d'irradiation des cancers de prostate de risque intermédiaire.	Prog Urol. 2016 Nov;26(13):793-794.	2016	Supiot S , Delaroche G, Latorzeff I, Magne N, Créhange G, Carrie C, Pommier P, Martin E, Bera G, Rio E, Paumier A, Martin J, Levine M, Julian J, Lukka H, Catton C.	N10		

High-Dose Hypofractionated Radiation Therapy for Noncompressive Vertebral Metastases in Combination With Zoledronate: A Phase 1 Study.	Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):840-847	2016	Pichon B, Campion L, Delpont G, Thillays F, Carrie C, Cellier P, Pommier P, Laude C, Mervoyer A, Hamidou H, Mahé MA, Supiot S.	N10	
Can We Spare the Pancreas and Other Abdominal Organs at Risk? A Comparison of Conformal Radiotherapy, Helical Tomotherapy and Proton Beam Therapy in Pediatric Irradiation.	PLoS One. 2016 Oct 20;11(10):e0164643.	2016	Jouglar E, Wagner A, Delpont G , Campion L, Meingan P, Bernier V, Demoor-Goldschmidt C, Mahé MA , Lacornerie T, Supiot S.	N10	
[Role of radiotherapy in the management of node-positive prostate cancer].	Cancer Radiother. 2016 Oct;20(6-7):442-4.	2016	Supiot S , Doré M, Rio E, Cellier P, Mesguez-Nebout N, Goineau A.	N10	
Comparison of Automated Atlas-Based Segmentation Software for Postoperative Prostate Cancer Radiotherapy.	Front Oncol. 2016 Aug 3;6:178.	2016	Delpont G , Escande A, Ruff T, Darréon J, Fontaine J, Noblet C , Supiot S , Lacornerie T, Pasquier D.	N10	
[Radiotherapy of bone metastases].	Cancer Radiother. 2016 Sep;20 Suppl:S227-34.	2016	Thureau S, Vieillard MH, Supiot S , Lagrange JL.	N10	
[Radiotherapy for paediatric cancers].	Cancer Radiother. 2016 Sep;20 Suppl:S216-26.	2016	Laprie A, Padovani L, Bernier V, Supiot S , Huchet A, Ducassou A, Claude L.	N10	
[French organization of paediatric radiation treatment: Results of a survey conducted by the radiotherapy Committee of the French Society of Paediatric Cancers (SFCE)].	Cancer Radiother. 2016 Jul;20(5):395-9	2016	Demoor-Goldschmidt C, Claude L, Carrie C, Bolle S, Helfre S, Alapetite C, Jouin A, Padovani L, Ducassou A, Vigneron C, Le Prisé É , Huchet A, Stefan D, Kerr C, Nguyen TD, Truc G, Chapet S, Bondiau PY, Coche B, Muracciole X, Laprie A, Noël G, Leseur J, Habrand JL, Potet H, Ruffier A, Supiot S , Mahé MA, Bernier V.	N10, R2	1
[French experience in paediatric total body irradiation: A study from the radiotherapy committee of the Société française des cancers de l'enfant (SFCE)].	Cancer Radiother. 2016 Jun;20(4):304-7.	2016	Demoor-Goldschmidt C, Supiot S , Claude L, Carrie C, Mazon R, Helfré S, Alapetite C, Jouin A, Coche B, Padovani L, Muracciole X, Bernier V, Vigneron C, Noël G, Leseur J, Le Prisé É , Stefan D, Habrand JL, Kerr C, Bondiau PY, Ruffier A, Chapet S, Mahé MA.	N10, R2	1
Incidental Detection of a Hodgkin Lymphoma on 18F-Choline PET/CT and Comparison With 18FDG PET/CT in a Patient With Prostate Cancer: Reply.	Clin Nucl Med. 2016 Sep;41(9):746-7.	2016	Goineau A, Supiot S.	N10	
Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer.	Front Oncol. 2016 Feb 16;6:24.	2016	Dal Pra A, Locke JA, Borst G, Supiot S , Bristow RG.	N10	
Stereotactic radiotherapy following surgery for brain metastasis: Predictive factors for local control and radionecrosis.	Cancer Radiother. 2016 Dec 7.	2016	Doré M, Martin S, Delpont G , Clément K, Campion L, Thillays F.	N10	
[Image-guided radiotherapy].	Cancer Radiother. 2016 Sep;20 Suppl:S27-35.	2016	de Crevoisier R, Chauvet B, Barillot I, Lafond C, Mahé M, Delpont G.	N10	
DEMAT: A multi-institutional dosimetry audit of rotational and static intensity-modulated radiotherapy.	Phys Med. 2016 May;32(5):664-70.	2016	Lafond C, Chiavassa S , Bertaut C, Boussion N , Chapel N, Chapron L, Coste F, Crespín S, Dy G, Faye PA, Leleu C, Bouvier J, Madec L, Mesgouez J, Palisson J, Vela A, Delpont G.	B3, N10	1
[Small animal image-guided radiotherapy: A new era for preclinical studies].	Cancer Radiother. 2016 Feb;20(1):43-53.	2016	Delpont G , Frelin-Labalme AM, Heinrich S, Beaudouin V, Noblet C, Begue M, Le Deroff C, Pouzoulet F, Chiavassa S.	N10	
[Radiotherapy in localized stages of follicular and diffuse non-Hodgkin's lymphomas].	Cancer Radiother. 2016 Oct;20(6-7):530-4.	2016	Demoor-Goldschmidt C, Agape P, Barillot I , Mahé MA.	T3, N10	1
[Clinical to target volume margins determination in radiotherapy for anal cancers].	Cancer Radiother. 2016 Oct;20(6-7):645-50.	2016	Libois V, Mahé MA , Rio E, Maingon P.	N10	

[Radiotherapy of skin cancers].	Cancer Radiother. 2016 Sep;20 Suppl:S249-55.	2016	Hennequin C, Rio E, Mahé MA.	N10	
[Radiotherapy of breast cancer].	Cancer Radiother. 2016 Sep;20 Suppl:S139-46	2016	Hennequin C, Barillot I , Azria D, Belkacémi Y, Bollet M, Chauvet B, Cowen D, Cutuli B, Fourquet A, Hannoun-Lévi JM, Leblanc M, Mahé MA.	N10, T3	1
[Guidelines for external radiotherapy and brachytherapy: 2nd edition].	Cancer Radiother. 2016 Sep;20 Suppl:S4-7.	2016	Mahé MA, Barillot I , Chauvet B.	N10, T3	1
[Radiotherapy of lymphomas].	Cancer Radiother. 2016 Sep;20 Suppl:S244-8	2016	Barillot I, Mahé MA , Antoni D, Hennequin C.	N10, T3	1
[The irradiation process].	Cancer Radiother. 2016 Sep;20 Suppl:S8-S19.	2016	Barillot I , Chauvet B, Hannoun Lévi JM, Lisbona A , Leroy T, Mahé MA.	N10, T3	1
Diminished oligomerization in the synthesis of new anti-angiogenic cyclic peptide using solution instead of solid-phase cyclization.	Biopolymers. 2016 May;106(3):368-75	2016	Rubio S, Clarhaut J, Péraudeau E, Vincenzi M, Soum C, Rossi F, Guillon J, Papot S , Ronga L.	P3	
Designing 'Totem' C2 -Symmetrical Iron Porphyrin Catalysts for Stereoselective Cyclopropanations.	Chemistry. 2016 Sep 12;22(38):13599-612.	2016	Carminati DM, Intrieri D, Caselli A, Le Gac S, Boitrel B , Toma L, Legnani L, Gallo E.	R5	
Protonated hexaphyrin-cyclodextrin hybrids: molecular recognition tuned by a kinetic-to-thermodynamic topological adaptation.	Chem Commun (Camb). 2016 Jul 19;52(60):9347-50.	2016	Le Gac S, Boitrel B , Sollogoub M, Ménand M.	R5	
Spontaneous Tl(I)-to-Tl(III) oxidation in dynamic heterobimetallic Hg(II)/Tl(I) porphyrin complexes.	Chem Commun (Camb). 2016 Jan 11;52(3):517-20.	2016	Ndoyom V, Fusaro L, Roisnel T, Le Gac S, Boitrel B.	R5	
Hexaphyrin-Cyclodextrin Hybrids: A Nest for Switchable Aromaticity, Asymmetric Confinement, and Isomorphous Fluxionality.	Angew Chem Int Ed Engl. 2016 Jan 4;55(1):297-301.	2016	Ménand M, Sollogoub M, Boitrel B, Le Gac S.	R5	
Occupational radiation exposure of medical staff performing ⁹⁰Y-loaded microsphere radioembolization.	Eur J Nucl Med Mol Imaging. 2016 May;43(5):824-31.	2016	Laffont S , Rolland Y, Ardisson V , Edeline J, Pracht M, Le Sourd S, Rohou T, Lenoir L, Lepareur N, Garin E.	R1	
High Impact of Preferential Flow on ^{99m}Tc-MAA and ⁹⁰Y-Loaded Microsphere Uptake Correlation.	J Nucl Med. 2016 Nov;57(11):1829-1830.	2016	Garin E , Edeline J, Rolland Y.	R1	
Pre- and per-treatment ¹⁸F-FDG PET/CT parameters to predict recurrence and survival in cervical cancer.	Radiother Oncol. 2016 Sep;120(3):512-518	2016	Leseur J, Roman-Jimenez G, Devillers A , Ospina-Arango JD, Guillaume D, Castelli J , Terve P, Lavoue V, Garin E , Lejeune F, Acosta O, De Crevoisier R.	R1, R2, R4	1
Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.	Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):635-43	2016	Edeline J, Crouzet L, Campillo-Gimenez B, Rolland Y, Pracht M, Guillygomarc'h A, Boudjema K, Lenoir L, Adhoute X, Rohou T, Boucher E, Clément B, Blanc JF, Garin E.	R1	
Clinical impact of (^{99m}Tc)-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (⁹⁰Y)-loaded microspheres.	Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):559-75.	2016	Garin E , Rolland Y, Laffont S, Edeline J.	R1	
Main applications of hybrid PET-MRI contrast agents: a review.	Contrast Media Mol Imaging. 2016 Mar-Apr;11(2):92-8.	2016	Kiani A, Esquevin A, Lepareur N, Bourguet P , Le Jeune F, Gauvrit J. Castelli J , De Bari B, Depeursinge A, Simon A, Devillers A, Roman Jimenez G , Prior J, Ozsahin M, de Crevoisier R , Bourhis J.	R1	
Overview of the predictive value of quantitative ¹⁸F-FDG PET in head and neck cancer treated with chemoradiotherapy.	Crit Rev Oncol Hematol. 2016 Dec;108:40-51.	2016		R1, R2, R4	1

Detection of bladder metabolic artifacts in (18)F-FDG PET imaging.	Comput Biol Med. 2016 Apr 1;71:77-85.	2016	Roman-Jimenez G, Crevoisier RD , Leseur J, Devillers A , Ospina JD, Simon A , Terve P, Acosta O .	R1, R2, R4	1
Is There a Role for Pelvic Irradiation in Localized Prostate Adenocarcinoma? Update of the Long-Term Survival Results of the GETUG-01 Randomized Study.	Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):759-769.	2016	Pommier P, Chabaud S, Lagrange JL, Richaud P, Le Prise E , Wagner JP, Azria D, Beckendorf V, Suchaud JP, Bernier V, Perol D, Carrie C.	R2	
[Expected benefit of lymph node and seminal vesical dissection to decrease high-risk prostate cancer radiotherapy].	Cancer Radiother. 2016 Jul;20(5):347-56.	2016	Colliaux J, Kharchi L, Vincendeau S, Simon A , Perdrieux M, Le Prisé É, Bellisant É, Castelli J, de Crevoisier R .	R2, R4	1
SU-G-1eP2-04: Dosimetric Accuracy of a Monte Carlo-Based Tool for Cone-Beam CT Organ Dose Calculation: Validation Against OSL and XRQA2 Film Measurements.	Med Phys. 2016 Jun;43(6):3656.	2016	Chesneau H, Lazaro D, Blideanu V, Lafond C .	R2	
A Nomogram to predict parotid gland overdose in head and neck IMRT.	Radiat Oncol. 2016 Jun 8;11:79.	2016	Castelli J, Simon A , Rigaud B, Lafond C , Chajon E, Ospina JD, Haigron P, Laguerre B, Loubière AR, Benezery K, de Crevoisier R .	R2, R4	1
Interindividual registration and dose mapping for voxelwise population analysis of rectal toxicity in prostate cancer radiotherapy.	Med Phys. 2016 Jun;43(6):2721.	2016	Dréan G, Acosta O, Lafond C , Simon A, de Crevoisier R, Haigron P.		
Cyclam te1pa for ⁶⁴ Cu PET imaging. Bioconjugation to antibody, radiolabeling and preclinical application in xenografted colorectal cancer	RSC Advances, 2016, accepted	2016	M. Frindel, P. Le Saëc, M. Beyler, A.-S. Navarro, C. Saï-Maurel, A. Cyrille, M. Chérel, J.-F. Gestin, R. Tripier and A. Faivre-Chauvet	B4, N1	1
Modulating the Water Exchange Rate in Lanthanide(III) Complexes: the Labile Capping Bond Effect at Work	Chem. Eur. J., 2016 , accepted	2016	A. Rodríguez-Rodríguez, M. Regueiro-Figueroa, D. Esteban-Gómez, V. Patinec, R. Tripier , G. Tircsó, F. Carniato, M. Botta and C. Platas-Iglesias	B4	
Intracellular Transport Studies of Picolinate Macrocyclic Copper and Lanthanide Complexes.	Chemistry Select, 2016, 1, 4423–4429	2016	D. Santo Domingo Porqueras, M. Beyler, R. Tripier , M. Salerno.	B4	
Comparison of Choi criteria and Response Evaluation Criteria in Solid Tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres Yttrium-90 selective internal radiation therapy (SIRT).	European journal of radiology (2016), 85(8), 1445-52	2016	Beuzit Luc; Edeline Julien; Brun Vanessa; Gandon Yves; Ronot Maxime; Guillygomarc'h Anne; Boudjema Karim; Garin Etienne ; Rolland Yan,	R1	
			Total		51

N°	Ville	Organisme	Laboratoire/ service
A1	ANGERS	INSERM U 1066	Micro et nanomédecines biomimétiques
A2	ANGERS	ICO	Service de Médecine Nucléaire
A3	ANGERS	CHU	Service de Médecine Nucléaire
A4	ANGERS	CHU	Dpt de Neuro-chirurgie
A5	ANGERS	CHU	Dpt de Pneumologie
A6	ANGERS	ICO	Oncologie radiothérapique
B1	BREST	INSERM U1101	LATIM
B2	BREST	CHU	Médecine nucléaire
B3	BREST	CHU Morvan	Service de radiothérapie
B4	BREST	UMR CNRS 6521	Fac des sciences, dep Chimie
LR1	La Rochelle	UMR 7266 CNRS-ULR	LIENSS, Littoral ENvironnement Sociétés
N1	NANTES	INSERM U 892	CRCNA, Eq 13 "recherche en oncologie nucléaire"
N2	NANTES	INSERM U 892	CRCNA, Eq 14 "Radiobiologie et ciblage de l'endothélium"
N3	NANTES	INSERM U 957 EA3822	Physiopathologie de la Résorption Osseuse et Thérapie des tumeurs osseuses primitives
N4	NANTES	SUBATECH	Ecole des Mines de Nantes
N5	SAINT-HERBLAIN	ARRONAX	R&D
N6	NANTES	ONIRIS	AMAROC
N7	NANTES	CEISAM, UMR 6230	Equipe CORAIL "Catalysis, ORganometallic chemistry And syntheses of Ligands"
N8	NANTES	CHU	Service de Médecine Nucléaire
N9	ST HERBLAIN	ICO-René Gauducheau	Service de Médecine Nucléaire
N10	ST HERBLAIN	ICO-René Gauducheau	Département de radiothérapie
N12	NANTES	IRCCyN, UMR 6597	Eq iVC
O1	ORLEANS	CIPA-TAAM	UPS n°44
O2	ORLEANS	CNRS	CEMHTI
O3	ORLEANS	CBM CNRS UPR4301	Centre de Biophysique Moléculaire
P1	POITIERS	CHU	Service de médecine nucléaire
P2	POITIERS	CHU	Service d'Oncologie radiothérapique
P3	POITIERS	UMR CNRS 7285	Eq « Systèmes Moléculaires Programmés »
R1	RENNES	CRLCC	Médecine Nucléaire
R2	RENNES	CRLCC	Service de radiothérapie
R3	RENNES	ENSCR	UMR 6226 – Institut des Sciences Chimiques de Rennes – équipe COS
R4	RENNES	INSERM U1099	Laboratoire du traitement du signal et de l'image
R5	RENNES	CNRS	Sciences chimiques de Rennes UMR CNRS 6226
R6	RENNES	INSERM U991	Foie, métabolismes et cancer
T1	TOURS	EA 6305	Aerosolthérapie et biomédicaments à visée respiratoires (ABVR)
T2	TOURS	CHRU	Service de Médecine Nucléaire et Ultrasons
T3	TOURS	CHRU	Service Oncologie Radiothérapie
T4	TOURS	EA 6295 -Fac de pharma	Nanomédicaments et nanosondes
T5	TOURS	INSERM UMR 930 "Imagerie et Cerveau"	Equipe "Ultrasons & Imagerie"